Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning ...

Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

The Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc.

BPDCN is an aggressive hematologic malignancy with a historically poor prognosis; VisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and me ...